Recent studies suggested that targeting the TNF signal pathway might comprise a viable therapeutic strategy to reduce disease burden in ischaemic vascular disease progression, particularly endothelial dysfunction, chronic inflammation, and atherosclerotic plaque development (Hu et al., 2015; Kojima et al., 2016; Nash et al., 2019). The gene discussed is TNF; the disease is endothelial dysfunction.